ヌトリン-3aによる肺p53の活性化は,実験的な肺高血圧を予防し,逆転させます
Nathalie Mouraret1, Elisabeth Marcos, Shariq Abid
1Hôpital Henri Mondor, Service de Physiologie-Explorations Fonctionnelles, Créteil, France.
Circulation
|March 21, 2013
まとめ
Nutlin-3aは,肺動脈の滑らかな筋肉細胞の細胞衰老を誘導し,細胞増殖を制限することによって,肺高血圧 (PH) の潜在的な治療を提供します. このプロセネセンスの治療は,PHの重症度および関連する合併症を軽減することに有望であることが示されています.
科学分野:
- 細胞の老化は
- 腫瘍抑制タンパク質 腫瘍抑制タンパク質
- 心血管研究に関する研究.
背景:
- p53の活性化によって誘発される細胞衰老は,増殖性疾患の新たな戦略である.
- ニュートリンは,p53の調節体であるMDM2を阻害してp53.3を活性化させます.
- 肺高血圧 (PH) は,肺動脈の滑らかな筋肉細胞 (PA-SMC) の増殖を伴う.
研究 の 目的:
- PA-SMCにおけるNutlin-3a誘発の衰老がPHを治療できるかどうかを調査する.
- ヌトリン-3aの治療効果をPHモデルに測定する.
主な方法:
- Nutlin-3aは,培養されたヒトPA-SMCの治療である.
- PHのマウスモデル (慢性性低酸素症,SU5416/低酸素症,SM22-5HTT+マウス) を用いたインビボ試験.
- 衰老マーカー,p53経路の活性化,PHに関連するパラメータ (右心室高縮,肺動脈筋形成) の評価.
主要な成果:
- Nutlin-3aは,PA-SMCの衰老,成長停止,およびp53標的遺伝子発現をインビトロで誘発した.
- デイリーヌトリン-3a治療は,マウスの場合,投与量に依存してPHを低下させ,右心室高縮症,肺動脈筋化を引き起こした.
- Nutlin-3aはマウスモデルで確立されたPHを部分的に逆転させ,その効果にはp53とp21が必要でした.
- MDM2は改造された肺血管で発見され,治療目標としての可能性を示唆しました.
結論:
- Nutlin-3aは,肺高血圧の治療の可能性を示しています.
- ヌトリン-3aを用いたプロセネセンスのアプローチでPA-SMCをターゲットにすることは,PH治療に有望であることが示されています.
関連する概念動画
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...


